Maetzold Derek J's Form 4 filing
Castle Biosciences Inc (CSTL) · filed Mar 22, 2024
- Accession no.
- 0001447362-24-000031
- Filed
- Mar 22, 2024
- Trade date
- Mar 20-21, 2024
- Filing delay
- 2 days
- Rule 10b5-1 plan
- Checked
This filing lists 14 non-derivative transactions. Open-market sales total $128.5K. It was filed 2 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Maetzold Derek JCIK 0001239501 | Director, Officer (Pres. & Chief Exec. Officer) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Mar 20, 2024 | Common Stock | SSaleDisposed | −2,295 | $20.27F2 | −$46,519.65 | 69,806 | Direct | |
| Mar 20, 2024 | Common Stock | SSaleDisposed | −1,175 | $20.27F2 | −$23,817.25 | 88,579 | Indirect | |
| Mar 20, 2024 | Common Stock | SSaleDisposed | −1,175 | $20.27F2 | −$23,817.25 | 77,476 | Indirect | |
| Mar 20, 2024 | Common Stock | SSaleDisposed | −375 | $20.27F2 | −$7,601.25 | 10,468 | Indirect | |
| Mar 20, 2024 | Common Stock | SSaleDisposed | −374 | $20.27F2 | −$7,580.98 | 10,467 | Indirect | |
| Mar 20, 2024 | Common Stock | SSaleDisposed | −374 | $20.27F2 | −$7,580.98 | 10,467 | Indirect | |
| Mar 20, 2024 | Common Stock | SSaleDisposed | −374 | $20.27F2 | −$7,580.98 | 10,467 | Indirect | |
| Mar 21, 2024 | Common Stock | SSaleDisposed | −73 | $20.70 | −$1,511.1 | 69,733 | Direct | |
| Mar 21, 2024 | Common Stock | SSaleDisposed | −37 | $20.70 | −$765.9 | 88,542 | Indirect | |
| Mar 21, 2024 | Common Stock | SSaleDisposed | −37 | $20.70 | −$765.9 | 77,439 | Indirect | |
| Mar 21, 2024 | Common Stock | SSaleDisposed | −11 | $20.70 | −$227.7 | 10,457 | Indirect | |
| Mar 21, 2024 | Common Stock | SSaleDisposed | −12 | $20.70 | −$248.4 | 10,455 | Indirect | |
| Mar 21, 2024 | Common Stock | SSaleDisposed | −12 | $20.70 | −$248.4 | 10,455 | Indirect | |
| Mar 21, 2024 | Common Stock | SSaleDisposed | −12 | $20.70 | −$248.4 | 10,455 | Indirect |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F2
This transaction was executed in multiple trades at prices ranging from $20.07 to $20.42, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
Referenced by the price of 7 transactions in Table I.